EFFECT OF ‘SAPTAMRITA VATI’ AND ‘VIRECHANAKARMA’ IN TAMAKA SHWASA WITH SPECIAL REFERENCE TO BRONCHIAL ASTHMA

Phase 2

Not yet recruiting

• Conditions: Mild intermittent asthma. Ayurveda Condition: TAMAKASVASAH,

• Registration Number: CTRI/2021/04/033056
• Lead Sponsor: National Institute of Ayurveda Jaipur

Brief Summary

**Disease reference-**

Agnivesha, Charakasamhita, ChikitsaSthana, Hikkashwasa ChikitsaAdhyaya,

**Drug reference**-

1.*RasRatna Sammuchaya, Hikka Shwasa Chikitsa prakran 13/56,57,58,59 )*

*2. virechanakarma reference-*,Hikkashwasa Chikitsa Adhyaya, 17/21,

**3**.  ibidem, Charakasamhita, PanchkarameeyaSiddhi Adhayya 2/11, pg. no. 688

4. ibidem, Ashtanga Hridaya, DoshoparkramaneeyaAdhayaya 13/29,pg.no. 217

**5**. ibidem, Charakasamhita, Siddhisthana, Kalpana SiddhiAdhayya 1/6, pg. no. 677

ch.su 16/7-8.

**NEED OF STUDY:**

Current estimate suggest that 300 million people worldwide suffer from Asthmaand an additional 100 million may be diagnosed with asthma by 2025. Accordingto WHO, by the year 2020 asthma along with chronic obstruction pulmonarydisease will become the third leading cause of death8. With anestimated 1.5-2 crores asthma patients, at least one in every 10 asthma patientglobally lives in India. Globally, the economic costs associated with asthmaexceed those of TB and HIV/AIDS combined. Asthma is prevalent in all countries,whether they are developed or underdeveloped. In fact, over 80 percent ofasthma deaths according to the World Health Organization (WHO), occur in lowand lower-middle-income countries9.

 Line of treatment adopted in Bronchial Asthma includes the use of inhaler ofcorticosteroids, leukotriene receptor antagonist, methylxanthinesetc. After taking modern drugs patient quality of life still remainscompromised10.

As per A*yurvedic*classics main line of treatment for *Tamaka* *Shwasa* includeboth*Shodhana*and*Shamana Chikitsa*, *Acharya Charak* has described the *Shodhana* procedure as

 â€œ  ***तमके******तà¥******विरेचनमà¥******“ 11***

In *Shamana Chikitsa* the food or drug which i*sVata Karaka*and *Kapha Nashaka* or *KaphaKaraka*and *Vata Shamaka*is indicated and in singlearm treatment only *Vata Shamaka* or *Kapha Shamaka* C*hikitsa* isindicated.12

Variety of treatment modalities including *Shamana*and *Shodhana* have been described in *Ayurveda*formanagement of *Shwasa Roga*.

Considering these factors this study hasbeen planned to evaluate the efficacy of *Virechana* *Karma* and *SaptamritaVati* in *Tamaka Shwasa.*

**HYPOTHESIS:**

**Null Hypothesis [H****0****]**

*Saptamrita  Vati* and *Virechana  Karma* areequally effective in *Tamaka Shwasa*  (BronchialAsthma).

**Alternate Hypothesis[H1]**

*Saptamrita Vati* and *Virechana Karma* arenot equally effective in *Tamaka Shwasa*(Bronchial Asthma)

**FOLLOW UP**-  0,15th and 30th  day.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-01-05
• Last Update Posted: 2021-04-22

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• 1.Patients willing for trial and give consent.
• 2.Patients of age group 18 to 70 yrs of either sex.
• 3.Patients having signs and symptoms of Tamak Shwasa i.e., Shwasakrucchata, Kasa (cough), Pratishyaya (chronic rhinitis), Bhasankrucchata (difficulty in speech), Nidralpata (inadequate sleep), Ghurghuraka (audible sounds) 4.Patients fit for Virechana Karma.
• 5.Patients who is not taking any allopathic medication for Asthma.
• Mild & moderate cases of Bronchial Asthma.

Exclusion Criteria

• 1.Patients not willing for trial.
• 2.Age below 18 years and above 70 years of age of either sex.
• 3.Patients suffering from Pulmonary tuberculosis, Cardiac Asthma, Bronchogenic carcinoma, Chronic obstructive Productive disease, Pleural effusion 4.Status Asthmaticus 5.Patients suffering from serious heart diseases or any other serious health aliment.
• 6.Patient with rectal or vaginal prolapse 7.Pregnant and lactating women 8.Patients, who are unfit for Virechana Karma 9Patients, who is taking any allopathic medication for Asthma.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Improvement in clinical Symptoms of Tamaka Shwasa	30 days

Secondary Outcome Measures

Name	Time	Method
1.Changes in Asthma control questionnaire	2. Changes in Spirometry- FVC1% and PEFR

Trial Locations

Locations (1)

National Institute Of Ayurveda Jaipur; 🇮🇳 Jaipur, RAJASTHAN, India

National Institute Of Ayurveda Jaipur

🇮🇳Jaipur, RAJASTHAN, India

DR DIVYA AGRAWAL

Principal investigator

8349307983

drdivyaagrawal112@gmail.com